a b s t r a c t V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole BRAF inhibitor bearing a phenylpyrazole group (dimethyl-[2-(4-{5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyridin-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine, 1a) was identified as an active BRAF inhibitor. Based on this starting point, we synthesized a series of analogues leading to the discovery of 6-{2-[4-(4-methylpiperazin-1-yl)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j), with nanomolar activity in three assays: inhibition of purified mutant BRAF activity in vitro; inhibition of oncogenic BRAF-driven extracellular regulated kinase (ERK) activation in BRAF mutant melanoma cell lines; and inhibition of proliferation in these cells.
Introduction
The RAS-RAF-MEK-ERK pathway is hyper-activated in approximately 30% of human cancers, 1 where it stimulates cell growth and survival. This hyper-activation is caused in part by mutations in receptor tyrosine kinases, the small G-proteins of the RAS family, and the serine/threonine specific protein kinase BRAF. Mutations in BRAF (one of the three rapidly growing fibrosarcoma (RAF) genes in humans; the other two being ARAF and CRAF) occur in $2% of human cancers, and are particularly prevalent in cutaneous melanomas ($50% of cases). The most common mutation (90% frequency) is a glutamic acid for valine substitution at position 600 (V600E). 2 In cancer cells, V600E BRAF stimulates constitutive ERK activity and drives proliferation and survival, thereby providing essential tumor growth and maintenance functions.
V600E
BRAF also contributes to neoangiogenesis by stimulating vascular endothelial growth factor secretion. 4 Consequently, BRAF is an attractive validated therapeutic target in melanoma, and several BRAF inhibitors are currently under development and in clinical trials 5 and we have previously described type II BRAF inhibitors, targeting the inactive conformation of BRAF. 6, 7 Triarylimidazoles have been reported as inhibitor scaffolds for targeting the active kinase conformation kinase, for example p38 8 and RAF. 9, 10 The general structure of these latter kinase inhibitors contains a hinge-binding group, usually pyridine or pyrimidine ('ring A'), a central imidazole scaffold occupying the ribose position in the ATP-binding pocket ('ring C') and a substituted aromatic group interacting with the hydrophobic pocket (BPII according to Liao's nomenclature) 11 next to the gatekeeper residue ('ring B') (Fig 1) . The third aryl ring ('ring D') extends outside the ATP pocket towards the solvent. The co-crystal structure of BRAF with SB590885, a triarylimidazole BRAF inhibitor, indicates binding to the active conformation of BRAF and supports the described binding mode. 9 Therefore, these compounds are BRAF type I inhibitors.
Two examples of reported active triarylimidazole BRAF inhibitors, L-779450 and SB-590885, are also shown in Figure 1 . 12,9 These BRAF inhibitors contain an H-bond donor on 'ring B' (phenol or oxime, Fig. 1 ) that is essential for activity.
In order fully to exploit the BPII pocket of the active BRAF conformation, we designed novel type I BRAF inhibitors based on this scaffold, but with an H-bond donor pyrazole heterocycle substituent on 'ring B', as a potential functional bioisostere of indanoneoxime and chlorophenol. 4-(3-Pyrazolyl)phenyl ring B was proposed to target the BPII pocket of BRAF and consequently compound 1a was synthesized (Fig. 2) . Docking of this compound with the BRAF structure in the active conformation (pdb code 2FB8) showed the expected orientation of the compound, similar to SB590885, with the pyridyl ring A interacting with the hinge and the 4-(3-pyrazolyl)phenyl ring B occupying the BPII pocket (Fig. 2) . The geometry of the oxime in indanoneoxime inhibitors is dependent of the rest of the inhibitor: the co-crystal structure of BRAF with an indanoneoxime BRAF inhibitor with a pyrazole scaffold shows the oxime in E-geometry (pdb code 3D4Q), 13 whereas SB590885 co-crystallises in an opposite Z-orientation. Pleasingly, this compound was found to inhibit isolated full length V600E BRAF at low micromolar concentrations (IC 50 BRAF = 1.6 lM) and also to inhibit V600E BRAF signalling in melanoma cells (GI 50 SRB = 7.4 lM). Hit 1a was therefore used as starting point for the structure-activity relationship (SAR) exploration and structure optimization for new BRAF inhibitors.
Results and discussion

Chemistry
Two synthetic routes were designed to access the desired trisubstituted imidazoles: Figure 2 . Structure of phenylpyrazole hit 1a, and docking in BRAF structure. (A) Starting from the 2,4,5-tribromo-imidazole core, 2, and introducing the desired substituents in sequence (Scheme 1).
(B) Using the protected indanone oxime (ring B) and building the trisubstituted imidazole core (Scheme 2).
In the first approach, the 2,4,5-tribromo-imidazole was protected as a methoxymethyl (MOM) derivative 3, and converted using a two-step procedure to the 2-(4-dimethylaminoethoxyphenyl)-4,5-dibromoimidazole, 5. The Suzuki coupling of this intermediate with 1 equiv of 4-pyridylboronic acid led to the key intermediate 6. A second Suzuki coupling with 4-methoxybenzylprotected boronic acids 26, 29a-b, 37, 40 or 43 (see Schemes 5 and 6) followed by acidic deprotection of the MOM and 4-methoxybenzyl groups generated the final compounds 1a-c, 1e-g. MOM deprotection of intermediate 6 led to imidazole 7, which could be coupled directly with boronic acid 33, to afford compound 1d after 4-methoxybenzyl removal (Scheme 1).
The alternative route (B) is a modification of the synthesis reported by Takle et al. 10 The starting material 5-bromo-2,3-dihydro-1H-inden-1-one O-methyl oxime 10, was converted to the corresponding aldehyde 11 with nBuLi and (dimethylformamide) DMF, followed by coupling with 4-pyridylmethyleneoxy-t-butyldimethylsilane to afford intermediate 12.
After deprotection with tetrabutylammonium fluoride, the corresponding diol, 13, was submitted to a Swern oxidation affording the dione 14. The coupling of 14 with selected aldehydes afforded the imidazole core linked to a suitable ring D. The final deprotection of the N-methyl indanone oxime system yielded the ketones 16a-c, which were converted in the final tricyclic compounds 1h, 1j-k by condensation with trisdimethylamino-methane and hydrazine (see Scheme 2) . The triazole final compound 1i was obtained from intermediate 16b by nitrosation followed by the addition of hydrazine (Scheme 3).
Diarylfurans with aliphatic, aromatic or carboxamide solubilising groups were previously shown to be alternative scaffolds for the synthesis of BRAF inhibitors.
14 Consequently, we synthesized several furan analogues with our most active tricyclic pyrazole ring B. For the synthesis of the trisubstituted furan analogues, the starting material was methyl-2,3-dibromofuran-5-yl carboxylate 17. Using two consecutive Suzuki couplings with 4-pyridyl boronic acid followed by 1-(methoxyimino)-2,3-dihydro-1H-inden-5-ylboronic acid, the intermediate 19 was obtained. Basic hydrolysis of intermediate 19 with NaOH afforded the corresponding carboxylic acid, 20, followed by acidic hydrolysis to remove the oxime ether group and generate the ketone 21. Condensation with the desired amines, in the presence of diisopropylcarbodiimide, hydroxybenzotriazole and triethylamine in DMF, produced the key intermediates 22a-d. The condensation of 22a-d with hydrazine or methylhydrazine gave the desired final compounds 1l-o and 1p, respectively (Scheme 4). Since most of the boronic acids used in the synthesis of the imidazoles previously described in Scheme 1 are not commercially available, their preparation is summarized in Schemes 5 and 6.
SAR of ring B-phenylpyrazole
In order to identify new type I BRAF inhibitors with a triarylimidazole scaffold, compound 1a with 4-(3-pyrazolyl)phenyl as ring B was synthesized and found to be effective. The SAR of ring B was explored further, leading to the discovery of the more potent 1,4-dihydroindeno[1,2-c]pyrazole. Using this group, further SAR exploration of rings C and D was performed.
The biological activities of compounds 1a-p were assessed in three assays: (1) Inhibition of the isolated V600E BRAF kinase activity (IC 50 BRAF), measuring MEK1/2 phosphorylation as the endpoint. 15 An alternative BRAF fluorescent ligand binding assay 10 Table 1 .
Our assessment of substitution of the pyrazole ring focused on the 4-position, since no further space is available for position 5 based on modelling studies of 1a with the BRAF structure reported in the co-crystal structure with SB590885 ( Fig. 2) . 9 Substitution in the 4-position of the pyrazole with methyl (compound 1b) is tolerated and beneficial. Larger substituents such as cyano or chlorine lead to loss of activity against both isolated BRAF and in cellular assays (1c, 1d). This effect could be due to a steric clash with the BRAF binding pocket or an unfavourable electrostatic interaction. In order to fix the position of the pyrazole ring, more rigid tricyclic systems were synthesized: 1e-h. The five-membered ring (1,4-dihydroindeno[1,2-c]pyrazole 1h) increases the potency against BRAF fivefold compared to the non-cyclic analogue 1b. This tricyclic system mimics the indanoneoxime moiety, with the oxime group in the E-geometry. Saturated or aromatic six-membered rings (1e, 1f) are not as effective as the five-membered ring. Methylation of the pyrazole leads to a loss in activity (1p vs 1l) consistent with the hypothesis that an H-donor group is beneficial for potent BRAF inhibition. Interestingly, the tricyclic triazole analogue 1i is inactive, possibly due to a polarity mismatch between the polar 3-position of the triazole (corresponding to the 5-position of the pyrazole) and a non-polar area of the BPII binding pocket. Similar results were observed with the tricyclic pyridazinone 1g, where the inactivity can be attributed to either polarity mismatch or steric clash. Since the 1,4-dihydroindeno[1,2-c]pyrazole 1h is the most active ring B, further optimization of rings C and D were performed keeping this ring B constant.
SAR of rings C and D
Furan-based analogues of SB-590885, where the core imidazole ring C was replaced by furan, with a variety of solubilizing D groups have been reported as potent BRAF inhibitors. 14 We have synthesized a number of furan-amides with our tricyclic pyrazole 'ring B' as BRAF inhibitors (1l-p), which were found to possess weaker activity against BRAF than their imidazole counterparts, but surprisingly good cellular activity (for example compound 1m has submicromolar activity in both IC 50 ppERK and GI 50 SRB assays). Modification of the substituents on the phenyl 'group D' (solubilizing group) of the imidazole inhibitors is expected to have a minimal effect on the BRAF potency but could modulate the cellular activity or the physicochemical properties of this series. Indeed, the replacement of the 2-dimethylaminoethoxy side chain of ring D (in 1h) with N-methylpiperazine lead to compound 1j, which is equipotent on BRAF IC 50 with 1h, but has improved cellular activity. Compound 1j has submicromolar activity in all 3 assays. Replacing the whole aryl ring D with a piperidine ring (1k) has a negative effect on BRAF potency, with a sixfold potency loss compared to 1h or 1j.
Pharmacokinetic (PK) data
The apparent clearance, half-life (t 1/2 ) and maximal plasma concentration of a representative tricyclic pyrazole, compound 1h, were determined in vivo in CD1 nu/nu female mice following an intraperitoneal administration of 1h. This compound exhibits a good PK profile, with a low plasma clearance (CL = 11 mL/min/kg), long half-life (T 1/2 = 3.9 h) and reaches plasma concentrations above its SRB cellular IC 50 (C max = 5.8 lM; IC 50 (SRB) = 1.1 lM).
Conclusion
A triarylimidazole BRAF inhibitor bearing a phenylpyrazole group (1a) was identified as an active BRAF inhibitor. Starting from this lead, optimization and SAR investigations led to the identification of the more potent tricyclic 1,4-dihydroindeno[1,2-c]pyrazole BRAF inhibitor 1h, with a favourable PK profile. Replacement of the imidazole core scaffold with furanamide led to compounds with weaker activity against isolated mutant BRAF, but with comparable Alliance 2795 HPLC system using 5 lm Atlantis C18, 50 mm Â 2.1 mm columns at 22°C with the following solvent system: aqueous: water + 0.1% formic acid; organic: 0.1% formic + acetonitrile, at a flow rate of 1 mL/min. Method A: gradient starting with 100% aqueous to 100% organic in 2.5 min at room temperature and a flow rate of 0.6 mL/min or method B gradient starting with 100% aqueous to 100% organic in 5 min at 40°C (column temperature) at a flow rate of 0.6 mL/min. UV detection was at 215 nm and ionisation was positive or negative ion electrospray. The molecular weight scan range was 50-1000. Samples were injected at 3 lL on a partial loop fill. All automated HPLC purification were performed on Gilson Prep LC modules running on software version 1.71 or 3.0 and on HyperprepHSC18 100 mm Â 21.2 mm columns, 12 lm, at a flow rate of 30 mL/min at room temperature using as aqueous phase: water + 0.1% (trifluoroacetic acid) TFA and as organic phase: acetonitrile + 0.1% TFA (UV detector, at 215 and 254 nm). The purity of the final compounds was determined by HPLC as described above and is 95% or higher unless specified otherwise. 1 
.480 mmol), 4-pyridyl-boronic ester (59 mg, 0.480 mmol), PPh 3 (12.6 mg, 0.048 mmol), and K 2 CO 3 (530 mg, 3.840 mmol) were suspended in a 2:1 mixture of DME/ H 2 O (9 mL). The suspension was stirred vigorously whilst de-gassing with N 2 for 20 min before adding Pd(OAc) 2 (5.4 mg, 0.024 mmol). The mixture was then refluxed for 2 h, cooled to room temperature, acidified to pH 1 with 1 M HCl and washed with EtOAc (3 Â 5 mL). The aqueous layer was basified with 2 M NaOH to pH 14 and extracted with EtOAc (3 Â 5 mL). This organic layer was dried (MgSO 4 ) and the solvent removed under vacuum. The residue was purified by chromatography using a stepped gradient of 5-10% NEt 3 
General method for the synthesis of {2-[4-(4-aryl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amines
Imidazole 6 or 7 (1 equiv), boronic ester (1.2-2 equiv), PPh 3 (0.1 equiv), and K 2 CO 3 (8-10 equiv) were suspended in a 2:1 mixture of DME/H 2 O (3-9 mL). The suspension was stirred vigorously whilst de-gassing with N 2 for 20 min before adding Pd(OAc) 2 (0.01 equiv). The mixture was then refluxed for 2 h to overnight, cooled to room temperature, acidified to pH1 with 1 M HCl and washed with EtOAc (3 Â 5 mL). The aqueous layer was basified with 2 M NaOH to pH14 and extracted with EtOAc (3 Â 5 mL). This organic layer was dried (MgSO 4 ) and the solvent removed under vacuum. The residue was purified by preparative HPLC to yield the desired product as TFA salt. 
(63 mg, 0.16 mol) and MOM protected imidazole 6 (57 mg, 0.13 mmol) gave the title compound which was purified by chromatography on silica gel. Yield = 60 mg (73%). 
-pyrazole-4-carbonitrile 37 (65 mg, 0.16 mol) and MOM protected imidazole 6 (57 mg, 0.13 mmol) gave the title compound which was purified by chromatography on silica gel. Yield = 61 mg (73%). 
The standard coupling procedure using 1-(4-methoxybenzyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5-dihydro-1H-benzo[g]indazole 40 (37 mg, 0.09 mmol) and imidazole 6 (31 mg, 0.07 mmol) resulted in 8e (13 mg, 29% 
.66 mmol) was dissolved in acetic acid (3 mL), diketone 14 (150 mg, 0.51 mmol) and ammonium acetate (393 mg, 5.10 mmol) was added. The reaction mixture was heated to 100°C and stirred for 1 h. Reaction mixture was basified with NH 3 , and diluted with water. Aqueous was extracted with DCM (3 Â 10 mL), dried (MgSO 4 ) filtered and evaporated under vacuum. Purification was carried out by Flash column chromatography on silica gel, eluting the desired product in 5-10% MeOH/DCM, to yield imidazole 15a. Yield: 93.5 mg (38%). 12 g, 1.6 mmol) . This solution was de-gassed with nitrogen for 20 min before being heated to 90°C overnight. The majority of DMF was then removed under vacuum and the crude diluted with EtOAc. The crude organic was washed with NaHCO 3 (1% aqueous) and dried (MgSO 4 ). Purification followed using flash column chromatography on silica gel eluting with EtOAc/heptane to yield 2.12 g of product (37%) as an off-white solid. 
4-(1-Oxo-2,3-dihydro-1H-inden-5-yl)-5-(pyridin-4-yl)furan-2-carboxylic acid (21).
To a solution of starting acid 20 (835 mg, 2.41 mmol) dioxane/acetone (8 mL:1.5 mL) was added 5 mL aqueous hydrochloric acid. The reaction was heated at 90°C for 90 min. Solvent was removed under vacuum to give 1.41 g of pure product (quantitative, some NaCl present). 
5-{5-[4-Morpholine-1-carbonyl]-2-pyridin-4-yl-furan-3-yl}-indan-1-one (22c).
Acid 21 (766 mg; 2.4 mmol) was coupled with morpholine (0.23 mL; 2.6 mmol) as described for 22a to give 22c. Yield = 520 mg (56%). 42 mmol) in HMPA (1.5 mL) and THF (5 mL) was added dropwise to the reaction mixture, which was then allowed to warm up to room temperature overnight. The reaction was quenched with NH 4 Cl saturated solution (50 mL) and extracted with EtOAc (3 Â 50 mL), the organic layer was dried (MgSO 4 ), filtered and the solvent removed under vacuum. The residue was purified by chromatography using a stepped gradient of 0-8% EtOAc in heptane to yield 24 as a white solid. Yield: 577 mg, 20%. 
3-(4-Bromo-phenyl)-1-(4-methoxy-benzyl)-1H-pyrazole (28a).
3-(4-Bromophenyl)pyrazole 27a (223 mg, 1 mmol) was dissolved in anhydrous DMF (2.2 mL) and added to 60% NaH in mineral oil (44 mg, 1.1 mmol) previously washed with diethyl ether. After stirring for 20 min at room temperature, 4-methoxybenzyl chloride (0.15 mL; 1.1 mmol) was added and stirring continued at room temperature for a further 4 h. Water (5 mL) was then added and the emulsion extracted with EtOAc (2 Â 3 mL). The combined organic phases were washed with saturated sodium bicarbonate (3 Â 2 mL) and dried (MgSO 4 ). After filtration and evaporation, the oil crystallised to give the product (352 mg, 100%). 4.1.6.5. 3-(4-Bromo-phenyl)-1-(4-methoxy-benzyl)-4-methyl-1H-pyrazole (28b). 4-Methyl-3-(4-bromophenyl)pyrazole 27b (474 mg, 2.0 mmol) was dissolved in anhydrous DMF (5 mL) and added to 60% NaH in mineral oil (88 mg, 2.2 mmol) previously washed with heptane. After stirring for 20 min at room temperature, 4-methoxybenzyl chloride (0.3 mL, 2.2 mmol) was added and stirring continued at room temperature for a further 3.5 h. Water (10 mL) was then added and the emulsion extracted with EtOAc (2 Â 10 mL). The combined organic phases were washed with saturated sodium bicarbonate (3 Â 20 mL) and dried (MgSO 4 ). After filtration and evaporation, the oil crystallised to give the product (697 mg, 98% and DMAP (9 mg; 0.1 mmol) were added and stirring continued at 0°C for 2 h and room temperature for 1 h. The reaction was diluted with EtOAc (2 mL) and washed with 1.2 N HCl (2 Â 2 mL), saturated sodium bicarbonate (2 mL) and brine (2 mL) before drying (Na 2 SO 4 ), filtering and evaporating to leave the product as an oil. Yield = 244 mg (92%). 
-(4-Bromo-benzoyl)-3-dimethylamino-acrylonitrile (34).
4-Bromophenyl-2 oxopropionitrile (448 mg, 2.0 mmol) was dissolved in DMF (2 mL) and tris(dimethylamino)methane (1.04 mL, 6.0 mmol) was added. The reaction was heated at 70°C for 4 h before cooling on ice and adding water (7 mL). The desired product was filtered off, washed with water and dried. Yield = 339 mg (61%). 3H, s) . The product was used in the next step without further purification.
3-(4-Bromo-phenyl)-1H-pyrazole-4-carbonitrile (35).
2-(4-Bromo-benzoyl)-3-dimethylamino-acrylonitrile 34 (339 mg, 1.22 mmol) was suspended in ethanol (3.4 mL) and hydrazine hydrate (77 mL, 1.58 mmol) was added. The starting material dissolved and the reaction was stirred at room temperature for 3 h. The solvent was evaporated and water (5 mL) added. The solid was filtered off and chromatographed on silica gel with 60:40 EtOAc/heptane to give the desired product (233 mg; 77%). Standard boronylation procedure (as described for compound 26) using 3-(4-bromo-phenyl)-1-(4-methoxy-benzyl)-1H-pyrazole-4-carbonitrile 36 (309 mg, 0.84 mmol) gave the desired compound (237 mg, 68% 4.1.7.5. 7-Bromo-4,5-dihydro-1H-benzo[g]indazole (38). 6-Bromo-3,4-dihydro-2H-naphthalen-1-one (204 mg, 0.91 mmol) was dissolved in DMF (2 mL) and tris-dimethylamino methane (657 mg, 4.53 mmol) was added. The reaction was stirred for 1 h, then further tris-dimethylamino methane (657 mg, 4.53 mmol) was added, and the reaction stirred overnight. The solvents were removed under vacuum and the residue azeothroped with heptane. The crude was then dissolved in AcOH (2 mL) and treated with NH 2 NH 2 ÁH 2 O (227 mg, 4.53 mmol). The reaction was stirred for 15 min, upon which concd NH 4 OH solution was added to pH 11. NaHCO 3 saturated solution (10 mL) was added and the aqueous layer was extracted with DCM (3 Â 10 mL), dried (MgSO 4 ) and the solvent removed in vacuo to yield 38 as a red brick solid. Yield: 224 mg, 99%. benzo[g]indazole 38 (90 mg, 0.36 mmol) was added in DMF (1 mL). The suspension was stirred for 10 min and PMBCl (61 mg, 0.39 mmol) was added dropwise. The reaction was stirred at room temperature for 1 h. Water (10 mL) was added and the aqueous layer was extracted with EtOAc (3 Â 10 mL). The organic layer was washed with water (2 Â 10 mL) and brine (10 mL), dried (MgSO 4 ), filtered, and the solvent removed under vacuum. The residue was purified by chromatography using 5% EtOAc in heptane to yield 39 as a yellow semi-solid. Yield: 62 mg, 47%. 
7-Bromo-1H-benzo[g]indazole (41).
Compound 38 (170 mg, 0.68 mmol) was dissolved in dioxane (6 mL) and DDQ (310 mg, 1.36 mmol) was added. The solution was refluxed for 3 h and the solvent was removed under vacuum. 2 M NaOH (10 mL) was added, and the aqueous layer was extracted with TBME (3 Â 10 mL), dried (MgSO 4 ) and the solvent removed under vacuum. The residue was purified by chromatography using a stepped gradient of 20-40% EtOAc in heptane to yield 41 as red brick solid. Yield: 81 mg, 48%. 4.1.7.9. 7-Bromo-1-(4-methoxy-benzyl)-1H-benzo[g]indazole (42). NaH (60% in mineral oil, 8.6 mg, 0.36 mmol) was suspended in DMF (2 mL) and 41 (81 mg, 0.33 mmol) was added in DMF (1 mL). The suspension was stirred for 10 min and PMBCl (56 mg, 0.36 mmol) was added dropwise. The reaction was stirred at room temperature for 1 h. Water (10 mL) was added and the aqueous layer was extracted with TBME (3 Â 10 mL). The organic layer was washed with water (2 Â 10 mL) and brine (10 mL), dried (MgSO 4 ), filtered, and the solvent removed under vacuum. The residue was purified by chromatography using 10% EtOAc in heptane to yield 42 as a yellow solid. Yield: 93 mg, 77%. were dissolved in TFA (1.5 mL) and heated at 130°C for 4 h then cooled to room temperature overnight. The solvent was evaporated, the residue washed with TBME and purified by preparative LC to give the desired compound (11 mg; 32% 
(18 mg; 0.03 mmol) was dissolved in TFA (0.5 mL) and heated at 65°C for 11 h then cooled to room temperature overnight. The solvent was evaporated, the residue washed with TBME to give the desired compound (19 mg; 76% 477.2400. The starting ketone 22b (34 mg, 0.07 mmol) was dissolved in dry DMF (0.5 mL) and DMFÁDMA (44 mg; 0.37 mmol) was added. The reaction was stirred for 90 min. The solvents were removed under vacuum and the residue azeotroped with heptane. The crude was then dissolved in AcOH (0.5 mL) and treated with methylhydrazine (51 mg; 1.11 mmol). The reaction was stirred at room temperature for two days, upon which concentrated NH 4 OH solution was added to pH 11. NaHCO 3 saturated solution (10 mL) was added and the aqueous layer was extracted with EtOAc (3 Â 10 mL), dried (MgSO 4 ) and the solvent removed under vacuum. The residue was purified by chromatography using a stepped gradient of 0-15% MeOH in DCM. The product was re-suspended in EtOAc (2 mL) and washed with water (5 Â 1 mL). The organic layer was dried (MgSO 4 ) and the solvent removed in vacuo to yield a pale yellow glue (3 mg; 8% 
Docking and modelling
Inhibitor 1a was docked using GOLD version 3.1.1[5] on the crystal structure of BRAF in complex with SB590885 [PDB 2FB8].
Partial charges of the ligand were derived using the Charge-2 CORI-NA 3D package in TSAR 3.3, and its geometry optimized using the COSMIC module of TSAR. The calculations were terminated if the energy difference or the energy gradient were smaller than 1E-005. Ten docking solutions were generated, and the best three stored for analysis.
Biology
4.3.1.
V600E
BRAF kinase assay and SRB IC 50 for BRAF inhibitors These assays have been described by Niculescu-Duvaz et al. 15 
Phospho-ERK IC 50 assay
To determine the effect of compounds on BRAF activity in cells, WM266.4 cells were seeded at a density of 3 Â 10 4 cells per well of a 96 well plate. The following day, test compounds were diluted into growth medium to 2Â the desired final concentration and then added directly to the cells. After a 6 h incubation, the medium was removed and cells were fixed and permeabilized in 4% formaldehyde, 0.1% triton X-100 in PBS for 30 min. The wells were then blocked with 5% milk in PBS for 30 min at room temperature, followed by the addition of an antibody for phospho-ERK1/2 (Sigma, Dorset, UK) at 3 mg/ml in blocking solution. Plates were incubated for 3 h with shaking.
Plates were washed three times with 0.1% Tween 20 using an ELx50 plate washer (BioTek, Winooski, USA). 0.5 mg/ml of a Europium-labelled anti-mouse secondary antibody (Perkin Elmer, Turku, Finland) was added to the wells in DELFIA assay buffer for 1 h. Plates were washed again and Enhancement solution was added to the wells and time resolved fluorescence was measured as instructed by the manufacturer after 20 min using a Spectramax M5 plate reader (Molecular Devices, Berkshire, UK). The plates were washed again and BCA protein assay reagent (Sigma, Dorset, UK) was added to the wells and incubated for 30 min at 37°C. Absorbance at 570 nm was measured using a plate reader and used to normalize the fluorescence data. Inhibition of ERK phosphorylation was determined as a percentage of DMSO-treated cells and IC 50 values were calculated using Prism (GraphPad Software, San Diego, USA).
PK assessment
Female Crl:CD1-Foxn1nu mice at least six weeks of age bearing mutant BRAF WM266.4 human tumor xenografts were used for the PK analyses. The mice were dosed intraperitoneally (4 mg/kg, equivalent to ca. 8 lmol/kg, 10 ml/kg, in 10% ethanol:40% PEG:50% Gelofusine v/v) in a cassette with 4 other compounds. Samples were taken at 8 time-points between 15 min and 24 h. Three mice were utilized per time-point. They were placed under isoflurane anaesthesia and blood for plasma preparation was taken by terminal cardiac puncture into heparinized syringes. Plasma samples were snap frozen in liquid nitrogen and then stored at À70°C prior to analysis. All procedures involving animals were performed in accordance with national Home Office regulations under the Animals (Scientific Procedures) Act 1986 and within guidelines set out by the Institute's Animal Ethics Committee and the United Kingdom Coordinating Committee for Cancer Research's ad hoc Committee on the Welfare of Animals in Experimental Neoplasia. 
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